Eli Lilly and Co
Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug […]
Read More
Eli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly‘s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company […]
Read More
Healthy Returns: Here’s what GLP-1s are being tested for beyond weight loss, diabetes
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The list of potential health benefits from […]
Read More
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over […]
Read More
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data […]
Read More
Here are JPMorgan’s top drug stock picks into earnings
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of 2024 have shifted and sparked a rotation out of large technology stocks into less-loved areas of the market, including value stocks and small caps. The […]
Read More
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
Sopa Images | Lightrocket | Getty Images Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, […]
Read More
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at stake, that’s pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. But the reality of the coming competition has grown more tangible after recent announcements from rival drugmakers Roche and […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a “very powerful duopoly.” “But […]
Read More